ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacubitril

Also written as “sacubitril/valsartan”, “Experimental: Sacubitril/Allisartan and Amlodipine Group” and “AHU377”.

Its studies are mostly in Heart Failure · Essential Hypertension · Chagas Disease · Myocardial Infarction · Isolated Systolic Hypertension, led by 4 companies.

Drug pageSacubitril: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 10, 201913 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only80 open or runningphase 4since Jul 10, 2019Oct 5, 2007none ahead
Shenzhen Salubris Pharmaceuticals20 open or runningphase 3since Jul 9, 2026Jul 9, 2026none ahead
Viatrisits history only22 open or runningphase 1since Jan 25, 2024Jan 25, 2024none ahead
Dr. Reddy's Laboratoriesits history only11 open or runningphase 1since Dec 12, 2023Dec 12, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shenzhen Salubris Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2026First studies: 2 phase 3 studies in Essential HypertensionFirst studyNCT07704697, NCT07704684

TargetBeta

DDR1 →MME →read by rule
“A neprilysn (NEP) inhibitor prodrug with natriuretic activity”NCIt, by rule
“Neprilysin inhibitor”ChEMBL 37, by rule

Studies

All 2 Shenzhen Salubris Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07704697Essential Hypertension · China3CompletedNov 10, 2025346
NCT07704684Essential Hypertension · China3CompletedAug 26, 2025376

How it is read

Names in the registry

  • “sacubitril/valsartan”, 5 entries
  • “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
  • “AHU377”, 2 entries
  • “Sacubitril/valsartan”, 1 entry
  • “Sacubitril and Valsartan Tablets 49mg/51mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.